The primary actors involved in this development are the Centers for Medicare & Medicaid Services (CMS), which finalized the rule, and the Pharmaceutical Research and Manufacturers of America (PhRMA), which initiated the legal challenge. Other stakeholders include the U.S. District Court for the District of Columbia, where the lawsuit is pending, and pharmaceutical manufacturers whose products fall under the GLOBE Model's criteria.

The Global Benchmark for Efficient Drug Pricing (GLOBE) Model is a mandatory payment model designed to lower the cost of drugs in Original Medicare Part B. It ties pricing benchmarks for certain high-spend, single-source drugs to international pricing data. The model excludes drugs already selected for the Medicare Drug Price Negotiation Program under the Inflation Reduction Act, as well as certain rare disease therapies and gene therapies. The rule requires manufacturers to submit detailed net pricing data, which CMS will use to calculate alternative rebate amounts.

The model applies to the United States healthcare system, specifically affecting Medicare Part B beneficiaries nationwide. The legal challenge is currently being adjudicated in the U.S. District Court for the District of Columbia.

The final rule was published in the Federal Register on October 2, 2026. The regulations are codified at 42 C.F.R. Part 513 and are scheduled to become effective on November 30, 2026. The model itself is set to begin operations on January 1, 2027, with a performance period starting April 1, 2027, and running for five years through March 31, 2032.

CMS states that the GLOBE Model is intended to address the rising costs of drugs in Medicare Part B while maintaining quality of care. The agency argues that using international reference prices provides a more efficient benchmark for drug pricing. Conversely, PhRMA and other industry critics argue that the model exceeds the agency's statutory authority under Section 1115A of the Social Security Act, which authorizes the testing of innovative payment models. Critics also contend that the model will stifle innovation by reducing the financial incentives necessary for pharmaceutical research and development.

The model operates through the Center for Medicare and Medicaid Innovation (CMMI), which has the authority to test new payment models. CMS will use international pricing data—sourced from private companies like IQVIA—to establish benchmarks. Manufacturers are required to report net pricing data; failure to comply or inability to provide the data may result in penalties. The model incorporates a rebate formula that adjusts payments based on the difference between the U.S. price and the international benchmark.

Why It Matters

This development represents a significant escalation in the federal government's efforts to control drug prices. By moving toward international reference pricing, the administration is attempting to align U.S. costs with global norms, a move that has profound implications for the pharmaceutical industry's business model and the future of drug innovation.

What Happens Next

The immediate focus is on the litigation in the D.C. District Court. The court's decision on a preliminary injunction will determine whether the model proceeds as scheduled on January 1, 2027. If the court stays the rule, the administration will face a significant setback in its drug pricing agenda.

Key Unknowns

It remains unclear how the court will interpret the scope of CMMI's authority in this context, especially given the history of similar models being blocked. Additionally, the long-term impact on pharmaceutical R&D investment remains a subject of intense debate among economists and industry analysts.

What to Watch

Watch for the court's ruling on the preliminary injunction and any subsequent statements from the White House or CMS regarding their contingency plans should the model be blocked. Additionally, monitor the pharmaceutical industry's compliance preparations as the November 30 effective date approaches.